Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Papadopoulos

Showing results (201-210 of 288) with videos related to

Pageof 29
Sort By:
ESMO Open|July 10, 2024
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignanciesM Saleh, M Barve, V Subbiah, et al.
Targeted Oncology|March 29, 2022
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid TumorsAmita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or LymphomaMonica M Mita, Patricia M LoRusso, Kyriakos P Papadopoulos, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumorsKyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
IEEE Transactions on Biomedical Circuits and Systems|October 2, 2023
Flexible Unipolar IGZO Transistor-Based Integrate and Fire Neurons for Spiking Neuromorphic ApplicationsAna Lebanov, Mauricio Velazquez Lopez, Florian De Roose, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 3, 2006
Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic dataKonstantinos Mimidis, Vassilios P Papadopoulos, Ioannis Elefsiniotis, et al.
British Journal of Cancer|June 6, 2014
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaA Patnaik, G J Weiss, K P Papadopoulos, et al.
Investigational New Drugs|March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsJeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Cancer|October 1, 1991
Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinomaA H Frank, P C Tseng, B G Haffty, et al.
Pageof 29

Showing results (201-210 of 288) with videos related to

Sort By:
Pageof 29
ESMO Open|July 10, 2024
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignanciesM Saleh, M Barve, V Subbiah, et al.
Targeted Oncology|March 29, 2022
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid TumorsAmita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or LymphomaMonica M Mita, Patricia M LoRusso, Kyriakos P Papadopoulos, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumorsKyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
IEEE Transactions on Biomedical Circuits and Systems|October 2, 2023
Flexible Unipolar IGZO Transistor-Based Integrate and Fire Neurons for Spiking Neuromorphic ApplicationsAna Lebanov, Mauricio Velazquez Lopez, Florian De Roose, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 3, 2006
Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic dataKonstantinos Mimidis, Vassilios P Papadopoulos, Ioannis Elefsiniotis, et al.
British Journal of Cancer|June 6, 2014
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaA Patnaik, G J Weiss, K P Papadopoulos, et al.
Investigational New Drugs|March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsJeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Cancer|October 1, 1991
Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinomaA H Frank, P C Tseng, B G Haffty, et al.
Pageof 29